Skip to main content
logo
Iovance Biotherapeutics, Inc. (FRA:2LB)
Germany flag Germany · Delayed Price · Currency is EUR
2.166
-0.102 (-4.50%)
At close: Jan 30, 2026

Iovance Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
250.43164.071.19---
Revenue Growth (YoY)
175.62%13698.99%----
Cost of Revenue
198.6112410.76---
Gross Profit
51.8240.08-9.57---
Selling, General & Admin
158.99153.02106.92104.183.6660.21
Research & Development
306.18282.34344.08294.78259.04201.73
Operating Expenses
463.15435.35450.99398.88342.7261.94
Operating Income
-411.33-395.28-460.56-398.88-342.7-261.94
Interest & Investment Income
10.0110.019.443.466.464.22
EBT Excluding Unusual Items
-401.82-385.27-451.12-395.42-336.24-257.72
Gain (Loss) on Sale of Investments
8.6310.263.61-0.47-6.01-1.87
Pretax Income
-398.33-375.01-447.52-395.89-342.25-259.58
Income Tax Expense
-0.7-2.83-3.48---
Net Income
-397.63-372.18-444.04-395.89-342.25-259.58
Net Income to Common
-397.63-372.18-444.04-395.89-342.25-259.58
Shares Outstanding (Basic)
332290235159153138
Shares Outstanding (Diluted)
332290235159153138
Shares Change (YoY)
19.46%23.28%47.64%3.82%10.92%11.23%
EPS (Basic)
-1.20-1.28-1.89-2.49-2.23-1.88
EPS (Diluted)
-1.20-1.28-1.89-2.49-2.23-1.88
Free Cash Flow
-351.82-364.05-384.11-313.18-265.52-251.93
Free Cash Flow Per Share
-1.06-1.26-1.63-1.97-1.73-1.82
Gross Margin
20.69%24.43%----
Operating Margin
-164.25%-240.92%-38734.99%---
Profit Margin
-158.78%-226.84%-37345.42%---
Free Cash Flow Margin
-140.49%-221.89%-32305.30%---
EBITDA
-375.79-362.11-439.14-389.57-339.59-260.8
EBITDA Margin
-150.06%-220.70%----
D&A For EBITDA
35.5433.1721.429.313.111.14
EBIT
-411.33-395.28-460.56-398.88-342.7-261.94
EBIT Margin
-164.25%-240.92%----
Revenue as Reported
250.43164.071.19---
Source: S&P Global Market Intelligence. Standard template. Financial Sources.